- 1.
Aaserud M, et al. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
Cochrane Database of Systematic Reviews. 2006;(2) CD005979. [
PubMed: 16625648]
- 2.
Austvoll-Dahlgren A, et al. Pharmaceutical policies: effects of cap and co-payment on rational drug use.
Cochrane Database of Systematic Reviews. 2008;(1) CD007017. [
PubMed: 18254125]
- 3.
Sturm H, et al. Pharmaceutical policies: effects of financial incentives for prescribers.
Cochrane Database of Systematic Reviews. 2007 [
PubMed: 17636851]
- 4.
Ball D. Working paper 3: Regulation of mark-ups in the pharmaceutical supply chain – review series on pharmaceutical pricing policies and interventions. Geneva: World Health Organization and Health Action International; 2011.
- 5.
Creese A. Working paper 5: Sales taxes on medicines – review series on pharmaceutical pricing policies and interventions. Geneva: World Health Organization and Health Action International; 2011.
- 6.
Saif A. Cost-plus price setting – WHO/HAI review series on pharmaceutical pricing policies and interventions. Unpublished.
- 7.
Espin J, Rovira J, Olry de Labry A. Working paper 1: External reference pricing – review series on pharmaceutical pricing policies and interventions. Geneva: World Health Organization and Health Action International; 2011.
- 8.
Kaplan WA, et al. Policy options for promoting the use of generic medicines in low- and middle-income countries – WHO/HAI review series on pharmaceutical pricing policies and interventions. Unpublished.
- 9.
Pillay T. Value based price determination – pharmacoeconomics – WHO/HAI review series on pharmaceutical pricing policies and interventions. Unpublished.
- 10.
Sarmiento AZ. Alternative drug pricing policies in the Americas. Geneva: World Health Organization; 1995. WHO health economics and drugs series No. 1 WHO/DAP/95.6.
- 11.
- 12.
- 13.
- 14.
- 15.
- 16.
Database of medicine prices, availability, affordability and price components. Geneva: World Health Organization and Health Action International; 2008. [October 2012].
http://www.haiweb.org/MedPriceDatabase/ - 17.
Meng Q, et al. The impact of China's retail drug price control policy on hospital expenditures: a case study in two Shandong hospitals.
Health Policy and Planning. 2005;20(3):185–196. [
PubMed: 15840634]
- 18.
Sun Q, et al. Pharmaceutical policy in China.
Health Affairs. 2008;27(4):1042–1050. [
PubMed: 18607039]
- 19.
Yu X, et al. Pharmaceutical supply chain in China: current issues and implications for health system reform.
Health Policy. 2010;97(1):8–15. [
PubMed: 20307912]
- 20.
Yang H, et al. Prices, availability and affordability of essential medicines in rural areas of Hubei Province, China.
Health Policy and Planning. 2010;25(3):219–229. [
PubMed: 19955093]
- 21.
- 22.
- 23.
Carasso BS, et al. Availability of essential medicines in Ethiopia: an efficiency-equity trade-off?
Tropical Medicine &; International Health. 2009;14(11):1394–1400. [
PubMed: 19754520]
- 24.
- 25.
Sarley D, et al. Ghana: Pharmaceutical pricing study. Policy analysis and recommendations. Arlington, VA: John Snow Inc/DELIVER for USAID; 2003.
- 26.
McCabe A. Private sector pharmaceutical supply and distribution chains: Ghana, Mali and Malawi. Washington DC: World Bank, Africa Region Health Systems for Outcomes Program; 2009. (HSO Publication 53107)
- 27.
- 28.
- 29.
Godwin SK, Varatharajan D. Drug price differentials across different retail market settings. An analysis of retail prices of 12 commonly used drugs. Health Administrator (India). 2006;XIX(1):41–47.
- 30.
- 31.
Perspectives and practice in antiretroviral treatment; mission for essential drugs and supplies, Kenya; a case study. Geneva: World Health Organization; 2004.
- 32.
Levison L, Kimatu S. Price components and essential medicines in Nairobi, Kenya: report to WHO. 2008. (unpublished)
- 33.
- 34.
Waning B, et al. Balancing medicine prices and business sustainability: analyses of pharmacy costs, revenues and profit shed light on retail medicine mark-ups in rural Kyrgyzstan.
BMC Health Service Research. 2010;10:205. [
PMC free article: PMC2914726] [
PubMed: 20626904]
- 35.
- 36.
- 37.
Maïga MD, Diawara A. Etude sur la disponibilité et les prix des medicaments dans le secteur prive au Mali [Study of the availability and price of medicines in the private sector of Mali]
Médecine Tropicale. 2006;66(6):565–568. [
PubMed: 17286022]
- 38.
Maïga D, Williams-Jones B. Assessment of the impact of market regulation in Mali on the price of essential medicines provided through the private sector.
Health Policy. 2010;97(2-3):130–135. [
PubMed: 20435368]
- 39.
Russo G, McPake B. Medicine prices in urban Mozambique: a public health and economic study of pharmaceutical markets and price determinants in low-income settings.
Health Policy and Planning. 2010;25(1):70–84. [
PubMed: 19843636]
- 40.
Rao R, Thapa D.
Nepal: reproductive health commodity pricing survey: understanding equity, access, and affordability of essential reproductive health commodities. Arlington, VA: John Snow Inc/DELIVER for USAID; 2005. [October 2010].
http://pdf.usaid.gov/pdf_docs/PNADG034.pdf.
- 41.
- 42.
Abdou Sidikou B, Moumouni H, Fanamy Mamadou I. Etude de la distribution des antipaludéens sur le secteur privé au Niger dans le but de renseigner la proposition “Affordable Medicines Facility – malaria (AMFm)”. [Study of the distribution of antimalarials in the private sector of Niger for the proposed “Affordable Medicines Facility – Malaria (AMFm)”]. Ministry of Public Health and Epidemic Control; Republic of Niger: 2009. Centre de Recherches Médicales et Sanitaires (CERMES) [Centre of Medical and Health Research]
- 43.
Mokuolu OA, et al. Effect of artemisinin-based treatment policy on consumption pattern of antimalarials.
Am J Trop Med Hyg. 2007;76(1):7–11. [
PubMed: 17255221]
- 44.
Madden J, et al. Measuring medicine prices in Peru: validation of key aspects of WHO/HAI survey methodology.
Revista Panamericana de Salud Pública. 2010;27(4):291–299. [
PubMed: 20512232]
- 45.
Russian economic report No. 19, June 2009. New York, NY: World Bank; 2009.
- 46.
- 47.
Guimier JM, et al. Why drug prices are high in sub-Saharan Africa. Analysis of price structure: the case of Senegal.
Cahiers d'études et de recherches francophones / Santé 2005;15(1):41–52. [
PubMed: 15919632]
- 48.
- 49.
South Africa. R.1090 Medicines and related substances act 1965: Regulations relating to a transparent pricing system for medicines and scheduled substances: Amendment (Dispensing fee for pharmacists). Government Gazette. 2010
- 50.
- 51.
- 52.
Battersby A, et al. Improving the supply, distribution and use of antimalarial drugs by the private sector in Tanzania. London: Malaria Consortium; 2003.
- 53.
Pitaknetinan K, et al. Profit, payment and pharmaceutical practices: perspectives from hospitals in Bangkok.
Health Policy. 1999;46(3):179–194. [
PubMed: 10351667]
- 54.
Auton M, Coghlan R, Maija A. Understanding the antimalarials market: Uganda 2007. An overview of the supply side. Geneva: Medicines for Malaria Venture; 2008.
- 55.
Coughlan R, Auton M, Maija A. Supply chain and price components of antimalarial medicines: Uganda 2007. Geneva: Medicines for Malaria Venture; 2008.
- 56.
- 57.
Courtois X, Dumoulin J. Sale of drugs and health care utilization in a health care district in Zaire.
Health Policy and Planning. 1995;10(2):181–186. [
PubMed: 10172351]
- 58.
- 59.
- 60.
- 61.
Olcay M, Laing R. Pharmaceutical tariffs: what is their effect on prices, protection of local industry and revenue generation? Geneva: Commission on Intellectual Property Rights, Innovation and Public Health, World Health Organization; 2005.
- 62.
Developing countries' duties and taxes on essential medicines used in the treatment of the major communicable diseases. Brussels: European Commission; 2003. European Commission Working Document.
- 63.
Goldman DP, et al. Prescription drug cost sharing: associations with medication and medical utilization and spending and health.
Journal of the American Medical Association. 2007;298(1):61–69. [
PMC free article: PMC6375697] [
PubMed: 17609491]
- 64.
Birch S. Relationship between increasing prescription charges and consumption in groups not exempt from charges.
Journal of the Royal College of General Practitioners. 1986;36(285):154–156. [
PMC free article: PMC1960399] [
PubMed: 3735198]
- 65.
Gemmill M, et al. What impact do prescription drug charges have on efficiency and equity? Evidence from high-income countries.
International Journal for Equity in Health. 2008;7:12. [
PMC free article: PMC2412871] [
PubMed: 18454849]
- 66.
Simon JL, et al. How will the reduction of tariffs and taxes on insecticide- treated bednets affect household purchases?
Bulletin of the World Health Organization. 2002;80(11):892–899. [
PMC free article: PMC2567679] [
PubMed: 12481212]
- 67.
- 68.
Creese A. Working paper 5: Sales taxes on medicines – review series on pharmaceutical pricing policies and interventions. Geneva: World Health Organization and Health Action International; 2011.
- 69.
Levison L, Laing R. The hidden costs of essential medicines. Essential Drugs Monitor. 2003;(33):20–21.
- 70.
Richter A. Assessing the impact of global price interdependencies.
PharmacoEconomics. 2008;26(8):649–659. [
PubMed: 18620459]
- 71.
Stargardt T, Schreyögg J. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.
Applied Health Economics and Health Policy. 2006;5(4):235–247. [
PubMed: 17249840]
- 72.
Garcia Mariñoso B, et al. External referencing and pharmaceutical price negotiation.
Health Economics. 2011;20(6):737–756. [
PubMed: 20577969]
- 73.
Håkonsen H, et al. Price control as a strategy for pharmaceutical cost containment - what has been achieved in Norway in the period 1994-2004?
Health Policy. 2009;90(2-3):277–285. [
PubMed: 19042052]
- 74.
- 75.
Akaleephan C, et al. Extension of market exclusivity and its impact on the accessibility to essential medicines, and drug expense in Thailand: analysis of the effect of TRIPs-Plus proposal.
Health Policy. 2009;91(2):174–182. [
PubMed: 19150741]
- 76.
Ford N, et al. Tough choices: tenofovir, tenders and treatment. Southern African Journal of HIV Medicine. 2012;9(1):8–10.
- 77.
Supakankunti S, et al. Impact of the World Trade Organization TRIPS agreement on the pharmaceutical industry in Thailand.
Bulletin of the World Health Organization. 2001;79(5):461–470. [
PMC free article: PMC2566431] [
PubMed: 11417042]
- 78.
Waning B, et al. Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases.
Bulletin of the World Health Organization. 2009;87(7):520–528. [
PMC free article: PMC2704041] [
PubMed: 19649366]
- 79.
Caves R, et al. Patent expiration, entry, and competition in the U.S. pharmaceutical industry. Brookings Papers: Microeconomics. 1991
- 80.
Kanavos P, et al. Competition in off-patent drug markets Issues regulation and evidence. Economic Policy. 2008;23(55):499–544.
- 81.
- 82.
Chen CL, et al. The influences of Taiwan's generic grouping price policy on drug prices and expenditures: evidence from analysing the consumption of the three most-used classes of cardiovascular drugs.
BMC public health. 2008;8:118. [
PMC free article: PMC2377257] [
PubMed: 18405385]
- 83.
Gibson TB, et al. The effects of prescription drug cost sharing: a review of the evidence.
American Journal of Managed Care. 2005;11(11):730–740. [
PubMed: 16268755]
- 84.
McManus P, et al. Impact of the minimum pricing policy and introduction of brand (generic) substitution into the pharmaceutical benefits scheme in Australia.
Pharmacoepidemiology and Drug Safety. 2001;10(4):295–300. [
PubMed: 11760489]
- 85.
Andersson K, et al. What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden.
Pharmacoepidemiology and Drug Safety. 2005;14(5):341–348. [
PubMed: 15624198]
- 86.
- 87.
Lim D, et al. A systematic review of the literature comparing the practices of dispensing and non-dispensing doctors.
Health Policy. 2009;92(1):1–9. [
PubMed: 19269055]
- 88.
Meyer J, et al. Randomized, controlled trial of prescribing training in a South African province.
Medical Education. 2001;35(9):833–840. [
PubMed: 11555220]
- 89.
Tsiantou V, et al. Generic medicines: Greek physicians' perceptions and prescribing practices.
Journal of Clinical Pharmacy and Therapeutics. 2009;34(5):547–554. [
PubMed: 19744010]
- 90.
- 91.
Al-Gedadi NA, Hassali MAA. Pharmacists' views on generic medicines: a review of the literature. Journal of Generic Medicines. 2008;5:209–218.
- 92.
Din Babar Z, Awaisu A. Evaluating community pharmacists' perceptions and practices on generic medicines: A pilot study from Peninsular Malaysia. Journal of Generic Medicines. 2008;5:315–330.
- 93.
Nsimba S. Assessing the performance, practices and roles of medicine sellers/dispensers and mothers'/guardians' behaviour for common childhood conditions in Kibaha district, Tanzania.
Tropical Doctor. 2007;37(4):197–201. [
PubMed: 17988473]
- 94.
Maïga F, et al. Public and private sector responses to essential drugs policies: a multilevel analysis of drug prescription and selling practices in Mali.
Social Science &; Medicine. 2003;57(5):937–948. [
PubMed: 12850118]
- 95.
James C, et al. An unhealthy public-private tension: pharmacy ownership, prescribing, and spending in the Philippines.
Health Affairs. 2009;28(4):1022–1033. [
PubMed: 19597201]
- 96.
Palmer L, Lisk D. Who prescribe better: doctors or dispensers?
World Health Forum. 1997;18:352–354. [
PubMed: 9478161]
- 97.
Andersson K, et al. Influence of mandatory generic substitution on pharmaceutical sales patterns: a national study over five years.
BMC Health Services Research. 2008;8:50. [
PMC free article: PMC2276486] [
PubMed: 18312635]
- 98.
Timonen J, et al. The impact of generic substitution on the turnover and gross margin of pharmaceutical companies a survey 1 year and 5 years after the introduction of generic substitution in Finland.
Health Policy. 2009;92(2-3):116–123. [
PubMed: 19346023]
- 99.
Bertoldi A, et al. Generic drugs in Brazil: known by many, used by few.
Cadernos de Saude Publica. 2005;21(6):1808–1815. [
PubMed: 16410866]
- 100.
Patel A, et al. “This body does not want free medicines”: South African consumer perceptions of drug quality.
Health Policy and Planning. 2010;25(1):61–69. [
PubMed: 19726560]
- 101.
- 102.
Sedjo R, Cox E. The influence of targeted education on medication persistence and generic substitution among consumer-directed health care enrollees.
Health Services Research. 2009;44(6):2079–2092. [
PMC free article: PMC2796315] [
PubMed: 19780849]
- 103.
- 104.
Valles J, et al. Acceptance of generic prescribing in general practice: effect of patient education and reference prices.
Gaceta Sanitaria. 2002;16(6):505–510. [
PubMed: 12459133]
- 105.
Himmel W, et al. Changes in drug prescribing under the Public Health Reform Law–a survey of general practitioners' attitudes in East and West Germany.
International Journal of Clinical Pharmacology and Therapeutics. 1997;35(4):164–169. [
PubMed: 9112138]
- 106.
Tilyard M, et al. General practitioners' views on generic medication and substitution.
New Zealand Medical Journal. 1990;103(893):318–320. [
PubMed: 2371006]
- 107.
Garattini L, Tediosi F. A comparative analysis of generics markets in five European countries.
Health Policy. 2000;51(3):149–162. [
PubMed: 10720685]
- 108.
Pavcnik N. Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
Rand J Econ. 2002;33(3):469–487. [
PubMed: 12585303]
- 109.
Brekke K, et al. Evaluering av ny apoteklov og indeksprissystemet. Vol. Rapport 17. Bergen: Rokkansenteret; 2003.
- 110.
Bardey D, et al. Retail price regulation and innovation: reference pricing in the pharmaceutical industry.
Journal of Health Economics. 2010;29(2):303–316. [
PubMed: 20053474]
- 111.
- 112.
King D, Kanavos P. Encouraging the use of generic medicines: implications for transition economies.
Croatian Medical Journal. 2002;43(4):462–469. [
PubMed: 12187525]
- 113.
Puig-Junoy J. Impact of European pharmaceutical price regulation on generic price competition: a review.
PharmacoEconomics. 2010;28(8):649–663. [
PubMed: 20515079]
- 114.
Puig-Junoy J, Moreno-Torres I. Do generic firms and the Spanish public purchaser respond to consumer price differences of generics under reference pricing?
Health Policy. 2010;98(2-3):186–194. [
PubMed: 20630613]
- 115.
Simoens S, et al. Pharmaceutical policy regarding generic drugs in Belgium.
PharmacoEconomics. 2005;23(8):755–766. [
PubMed: 16097838]
- 116.
- 117.
Clement F, et al. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.
Journal of the American Medical Association. 2009;302(13):1437–1443. [
PubMed: 19809025]
- 118.
Anis AH, Gagnon Y. Using economic evaluations to make formulary coverage decisions. So much for guidelines.
PharmacoEconomics. 2000;18(1):55–62. [
PubMed: 11010604]
- 119.
Lee KS, et al. Introducing economic evaluation as a policy tool in Korea: will decision makers get quality information? A critical review of published Korean economic evaluations.
PharmacoEconomics. 2005;23(7):709–721. [
PubMed: 15987227]
- 120.
Teerawattananon Y, et al. A systematic review of economic evaluation literature in Thailand: are the data good enough to be used by policy-makers?
PharmacoEconomics. 2007;25(6):467–479. [
PubMed: 17523752]
- 121.
Yothasamut J, et al. Using economic evaluation in policy decision-making in Asian countries: mission impossible or mission probable?
Value in Health. 2009;12(11) Suppl 3:S26–S30. [
PubMed: 20586976]
- 122.
Williams I, et al. The use of economic evaluations in NHS decision-making: a review and empirical investigation.
Health Technology Assessment. 2008;12(7):1–175. [
PubMed: 18373906]
- 123.
Mason JM, Mason AR. The generalisability of pharmacoeconomic studies: issues and challenges ahead.
PharmacoEconomics. 2006;24(10):937–945. [
PubMed: 17002476]
- 124.
Sculpher MJ, et al. Generalisability in economic evaluation studies in healthcare: a review and case studies.
Health Technology Assessment. 2004;8(49):1–192. [
PubMed: 15544708]
- 125.
Neumann PJ, et al. Are key principles for improved health technology assessment supported and used by health technology assessment organizations?
International Journal of Technology Assessment in Health Care. 2010;26(1):71–78. [
PubMed: 20059783]
- 126.
Singer ME. Developing nations special issue.
PharmacoEconomics. 2009;27(11):887–889. [
PubMed: 19888789]
- 127.
Babar Z, Scahill S. Is there a role for pharmacoeconomics in developing countries?
PharmacoEconomics. 2010;28(12):1069–1074. [
PubMed: 21080732]
- 128.
- 129.
Spencer Jones J. Pharmacoeconomics in South Africa.
South African Medical Journal. 2006;96(2):96. [
PubMed: 16541546]
- 130.
Tantivess S, et al. Strengthening cost-effectiveness analysis in Thailand through the establishment of the health intervention and technology assessment program.
PharmacoEconomics. 2009;27(11):931–945. [
PubMed: 19888793]
- 131.
Thatte U, et al. Evidence-based decision on medical technologies in Asia Pacific: experiences from India, Malaysia, Philippines, and Pakistan.
Value in Health. 2009;12:S18–S25. [
PubMed: 20586975]
- 132.
van Hulst M, et al. Health economics of blood transfusion safety – focus on sub-Saharan Africa.
Biologicals. 2010;38(1):53–58. [
PubMed: 20022523]
